Nilotinib in chronic myelogenous leukemia patients who failed prior imatinib and dasatinib therapy: Updated results of an open-label phase II study

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 7055-7055 ◽  
Author(s):  
E. Abruzzese ◽  
G. Alimena ◽  
P. le Coutre ◽  
K. N. Bhalla ◽  
G. J. Ossenkoppele ◽  
...  
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Myelogenous Leukemia ◽  
Open Label ◽  
Open Label Phase

Methotrexate-Paclitaxel-Epirubicin-Carboplatin (M-TEC) Combination Chemotherapy in Patients with Advanced Bladder Cancer: An Open Label Phase II Study

2005 ◽  
Vol 17 (4) ◽  
pp. 444-448 ◽  
Author(s):  
N. Tsavaris ◽  
C. Kosmas ◽  
H. Skopelitis ◽  
A. Dimitrakopoulos ◽  
P. Kopteridis ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Phase Ii ◽  
Combination Chemotherapy ◽  
Phase Ii Study ◽  
Open Label ◽  
Advanced Bladder Cancer ◽  
Open Label Phase

Treatment of Chronic Myelogenous Leukemia with Interleukin-2: A Phase II Study in 21 Patients

1999 ◽  
Vol 22 (2) ◽  
pp. 175-181 ◽  
Author(s):  
Norbert Vey ◽  
Didier Blaise ◽  
Marina Lafage ◽  
Daniel Olive ◽  
Patrice Viens ◽  
...  
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Interleukin 2 ◽  
Myelogenous Leukemia

scholarly journals Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)

2016 ◽  
Vol 27 ◽  
pp. vi233 ◽  
Author(s):  
S. Bozzarelli ◽  
L. Rimassa ◽  
L. Giordano ◽  
S. Sala ◽  
M.C. Tronconi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Pancreatic Cancer ◽  
Open Label ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document